

Compound S2. To a solution of compound $S1^{[1]}$ (0.48 g, 1.28 mmol) in DMF (30 mL) was added dropwise a solution of cesium hydroxide monohydrate (0.24 g, 1.43 mmol) in methanol (10 mL). The solution was stirred for 30 min and then a solution of I(CH₂CH₂O)₃CH₂CH₂N₃^[2] (0.84 g, 2.56 mmol) in 10 mL DMF was added in one portion. Stirring was continued for another 12 h and the solvent was then evaporated under vacuum. The resulting slurry was re-dissolved with dichloromethane (50 mL). The solution was washed with water (25 mL × 2) and brine (25 mL), and dried over anhydrous sodium sulfate. The solvent was then removed and the resulting crude product was subjected to column chromatography (n-hexane/ethyl acetate 4:1) to give compound **S2** as a brown oil (0.34 g, 50%). ¹H NMR (400 MHz, CD₃CN) δ : 6.67 (s, 1H), 6.56 (s, 1H), 3.68-3.50 (m, 12H), 3.38-3.33 (m, 2H), 2.98 (t,d, $J_1 = 6.7$ Hz, $J_2 = 1.2$ Hz, 2H), 2.94 (t,d, $J_1 = 6.2$ Hz, $J_2 = 1.2$ Hz, 2H), 2.72 (t,d, $J_1 = 6.7$ Hz, $J_2 = 1.7$ Hz, 2H). ¹³C NMR (100 MHz, CD₃CN) δ : 127.0, 125.0, 124.1, 124.0, 119.2, 71.2, 71.1, 70.5, 70.2, 51.5, 36.2, 31.6, 19.1 HRMS (ESI): Calcd for C₁₇H₂₂N₄O₃S₆: 522.0016 [M]⁺. Found: 522.0020.

Compound S3. To a solution of compound **S2** (0.34 g, 0.64 mmol) in DMF (20 mL) was added dropwise a solution of cesium hydroxide monohydrate (0.13 g, 0.77 mmol) in methanol (5 mL). After stirring for another 30 min, a solution of I(CH₂CH₂O)₃CH₂CO₂Me^[3](0.43 g, 1.29 mmol) in 6 mL DMF was added. The solution was stirred for 12 h and the solvent was evaporated under vacuum. The resulting residue was triturated with dichloromethane (50 mL). The solution was washed with water (25 mL × 2) and brine (25 mL), and dried over sodium sulfate. After the solvent was removed, the resulting crude product was subjected to column chromatography (n-hexane/ethyl acetate 1:1) to afford

compound **S3** as a brown oil (0.33 g, 77%). ¹H NMR (400 MHz, CD₃CN): δ 6.56 (s, 2H), 4.10 (s, 2H), 3.68 (s, 3H), 3.65-3.50 (m, 22H), 3.42-3.24 (m, 2H), 2.94 (t,d, $J_1 = 6.2$ Hz, $J_2 = 1.2$ Hz, 4H). ¹³C NMR (100 MHz, CD₃CN): δ 171.7, 127.2, 124.1, 124.0, 71.4, 71.2, 71.1, 71.0, 70.5, 70.1, 68.9, 52.1, 51.5, 36.1. HRMS(ESI): Calcd for C₂₃H₃₅N₃O₈S₆: 673.0748 [M]⁺. Found: 673.0722.

Compound S6. To a solution of compound S3 (0.33 g, 0.50 mmol) in THF (32 mL) was added a solution of lithium hydroxide monohydrate (0.81 g, 0.02 mol) in water (8 mL). The mixture was stirred at room temperature for 18 hours and then acidified with aqueous hydrochloric acid to pH = 3 and then concentrated under vacuum. The resulting residue was triturated with dichloromethane (20 mL). The solution was washed with water (10 mL \times 2) and brine (10 mL), and dried over anhydrous sodium sulfate. Removal of the solvent under reduced pressure yielded compound S4 as a yellow oil. Without further purification, the crude product was dissolved in dichloromethane (10 mL). To the solution were added N-methylmorpholine (61 mg, 0.60 mmol) and ethyl chloroformate (54 mg, 0.50 mmol). After stirring for 40 min at room temperature, a solution of compound S5^[3] (0.53 g, 0.5 mmol) in dichloromethane (10 mL) was added. Stirring was continued for another 12 h and then the solution was washed with water (10 mL \times 2) and brine (10 mL), and dried over sodium sulfate. Upon removal of the solvent with rotavapor, the resulting crude product was subjected to column chromatography (nhexane/ethyl acetate 1:2) to afford compound S6 as an orange solid (0.61 g, 73%). ¹H NMR (400 MHz, acetone-d₆): δ 10.34 (s, 1H), 10.24 (s, 1H), 9.19 (s, 1H), 8.78 (d,d, $J_1 = 8.1$ Hz, $J_2 = 1.3$ Hz, 1H), 8.69 $(d,d, J_1 = 8.1 \text{ Hz}, J_2 = 1.3 \text{ Hz}, 1\text{H}), 8.53 (d,d, J_1 = 8.1 \text{ Hz}, J_2 = 1.5 \text{ Hz}, 1\text{H}), 7.87-7.78 (m, 4\text{H}), 7.71 (t, 10.15)$ J = 5.5 Hz, 1H), 7.45 (d,d, $J_1 = 7.8$ Hz, $J_2 = 1.6$ Hz, 1H), 7.36 (m, 4H), 7.23 (t, J = 8.0 Hz, 1H), 7.14-7.02 (m, 3H), 6.99-6.88 (m, 2H), 6.68 (s, 1H), 6.60 (s, 1H), 4.26-4.19 (m, 4H), 4.15 (t, J = 6.2 Hz, 2H), 4.08 (s, 6H), 3.97 (s, 3H), 3.89-3.75 (m, 6H), 3.74-3.69 (m, 2H), 3.69-3.54 (m, 18H), 3.48-3.32 (m, 6H), 2.96 (t, J = 6.3 Hz, 2H), 1.99-1.80 (m, 6H), 1.71-1.62 (m, 2H), 1.61-1.52 (m, 2H), 1.48-1.30 (m, 16H), 1.20 (d, J = 6.9 Hz, 12H). ¹³C NMR (101 MHz, acetone-d₆): δ 169.0, 166.19, 163.7, 163.6, 155.6, 154.5, 148.8, 148.7, 148.1, 142.5, 133.8, 133.4, 132.8, 130.6, 129.9, 128.0, 127.8, 127.7, 127.3, 127.2, 126.7, 126.6, 126.1, 126.0, 125.9, 125.5, 125.4, 125.3, 125.1, 124.7, 124.1, 124.0, 123.8, 123.4, 123.3, 114.8, 114.7, 106.4, 106.3, 75.4, 72.1, 71.5, 71.4, 71.3, 71.2, 70.7, 70.4, 70.3, 68.9, 68.8, 63.9, 63.4, 63.0, 51.5, 40.4, 36.1, 36.0, 31.0, 30.5, 30.4, 30.2, 27.9, 27.2, 27.1, 24.4, 23.8. HRMS (ESI): Calcd for C₈₅H₁₁₁N₇O₁₆S₆Na: 1700.6309 [M+Na]⁺. Found: 1700.6312.



Compound S8. A solution of CuSO₄-5H₂O (4 mg), TBTA (2 mg), sodium ascorbate (0.38 g, 1.96

mmol), compound $\mathbf{S7}^{[4]}$ (0.16 g, 0.098 mmol), TsO(CH₂)₁₀N₃^[5] (45 mg, 0.098 mmol), and K₂CO₃ (40 mg, 0.29 mmol) in water/dicholoromethane/methanol (1.5 mL/5 mL/2.5 mL) was stirred for 12 h at room temperature and then concentrated under reduced pressure. The resulting residue was triturated with dichloromethane (10 mL). The organic phase was washed with water (50 mL × 3) and brine (5 mL), and dried over anhydrous sodium sulfate. Upon removal of the solvent, the resulting residue was subjected to column chromatography (DCM/MeOH 100:1) to give compound **S8** as a pale yellow oil (0.15 g, 77%). ¹H NMR (400 MHz, CDCl₃): δ 7.77 (d, *J* = 8.3 Hz, 2H), 7.50-7.26 (m, 43H), 6.68-6.63 (m, 12H), 6.61 (d, *J* = 1.5 Hz, 2H), 6.56 (t, *J* = 2.2 Hz, 4H), 6.55-6.52 (m, 3H), 5.01 (s, 16H), 4.95 (s, 12H), 4.65 (s, 2H), 4.52 (s, 2H), 4.27 (t, *J* = 7.2 Hz, 2H), 3.98 (t, *J* = 6.5 Hz, 2H), 2.42 (s, 3H), 2.06-1.96 (m, 2H), 1.89-1.79 (m, 2H), 1.34-1.12 (m, 12H). ¹³C NMR (100 MHz, CDCl₃): δ 160.2, 160.1, 160.0, 144.6, 140.4, 139.3, 139.2, 136.8, 133.2, 129.8, 128.5, 128.2, 127.9, 127.8, 127.5, 127.1, 106.7, 106.4, 101.6, 101.4, 72.3, 70.6, 70.0, 69.9, 63.7, 50.3, 30.2, 29.6, 29.2, 28.9, 28.8, 28.7, 26.4, 25.2, 21.6. HRMS (ESI): Calcd for C₁₂₅H₁₂₂N₃O₁₈S: 1984.8444 [M+H]⁺. Found: 1984.8423.



Compound S9. A solution of TsO(CH₂)₁₀N₃^[5] (0.56 g, 1.53 mmol), 1,5-dihydroxy naphthalene (1.6 g, 9.9 mmol) and potassium hydroxide (0.56 g, 9.9 mmol) in ethanol (40 mL) was heated under reflux for 24 h and then cooled to room temperature. Diluted hydrochloric acid was added to pH = 2. The solvent was then evaporated and the resulting residue was triturated dichloromethane (10 mL). The organic phase was washed with water (5 mL × 3) and brine (5 mL), and dried over sodium sulfate. The solvent was then removed and the crude product subjected to column chromatography (n-hexane/ethyl acetate 80:7) to afford compound **S9** as a brown solid (0.34 g, 65%). ¹H NMR (400 MHz, CDCl₃): δ 7.88 (d, *J* = 8.5 Hz, 1H), 7.71 (d, *J* = 8.5 Hz, 1H), 7.41-7.35 (m, 1H), 7.33-7.27 (m, 1H), 6.84 (t, *J* = 7.6 Hz, 2H), 5.20 (s, 1H), 4.13 (t, *J* = 6.4 Hz, 2H), 3.25 (t, *J* = 7.0 Hz, 2H), 1.96-1.87 (m, 2H), 1.58 (s, 6H), 1.40-1.31 (m, 8H). ¹³C NMR (100 MHz, CDCl₃): δ 125.5, 125.1, 115.1, 113.4, 109.5, 105.3, 68.3, 51.6, 29.6, 29.5, 29.5, 29.4, 29.2, 28.9, 26.8, 26.4. HRMS (ESI): Calcd for C₂₀H₂₈N₃O₂: 342.2182 [M+H]⁺. Found: 342.2165.

Compound S10. A solution of compounds **S9** (29 mg, 0.075 mmol), **S8** (150 mg, 0.075 mmol), K_2CO_3 (26 mg, 0.19 mmol) and 18-crown-6 (20 mg) in MeCN (10 mL) was heated under reflux for 24 h and then concentrated. The resulting residue was triturated with dichloromethane (10 mL). The organic

phase was washed with water (5 mL × 3) and brine (5 mL), and dried over by sodium sulfate. After the solvent was removed, the resulting residue was subjected to column chromatography (n-hexane/ethyl acetate 2:1) to afford compound **S10** as a white solid (0.11 g, 69%). ¹H NMR (400 MHz, CDCl₃): δ 7.93 (d, J = 8.4 Hz, 2H), 7.56-7.26 (m, 43H), 6.87 (d, J = 7.5 Hz, 2H), 6.75 (s, 12H), 6.70 (s, 2H), 6.67-6.58 (m, 7H), 5.06 (s, 16H), 5.01 (s, 12H), 4.73 (s, 2H), 4.60 (s, 2H), 4.30 (t, J = 7.0 Hz, 2H), 4.20-4.10 (m, 4H), 3.29 (t, J = 6.9 Hz, 2H), 2.00-1.87 (m, 6H), 1.69-1.57 (m, 6H), 1.51-1.25 (m, 20H). ¹³C NMR (101 MHz, CDCl₃): δ 160.3, 160.2, 160.1, 154.7, 145.1, 140.5, 139.4, 139.3, 136.8, 128.6, 128.0, 127.6, 127.2, 126.9, 125.2, 122.4, 114.2, 106.8, 106.5, 105.3, 101.7, 101.5, 72.4, 70.2, 70.1, 68.2, 63.8, 51.5, 50.4, 30.3, 29.8, 29.6, 29.5, 29.4, 29.4, 29.2, 29.0, 28.9, 26.8, 26.5, 26.3. HRMS (ESI): Calcd for C₁₃₈H₁₄₁N₆O₁₇: 2154.0353 [M+H]⁺. Found: 2154.0364.



Compound S12. A solution of CuSO₄-5H₂O (6 mg), TBTA (1.8 mg), sodium ascorbate (0.28 g, 1.39 mmol), compounds **S10** (0.15 g, 0.070 mmol) and **S11**^[6] (0.13 g, 0.42 mmol), and K₂CO₃ (35 mg, 0.21 mmol) in water/dicholoromethane/methanol (3 mL/10 mL/5 mL) was stirred for 12 h at room temperature and then concentrated under reduced pressure. The resulting slurry was triturated with dichloromethane (10 mL). The organic layer was washed with water (5 mL \times 3) and brine (5 mL), and dried over anhydrous sodium sulfate. The solvent was then removed and the resulting residue was subjected to column chromatography (n-hexane/ethyl acetate 1:1) to give compound S12 as an orange solid (59.3 mg, 34%). ¹H NMR (400 MHz, CDCl₃): δ 7.82 (d, J = 8.3 Hz, 2H), 7.65-7.55 (m, 5H), 7.47 (s, 1H), 7.43-7.28 (m, 42H), 6.82-6.77 (m, 2H), 6.70-6.62 (m, 12H), 6.62-6.57 (m, 2H), 6.57-6.50 (m, 7H), 5.03 (s, 2H), 5.01 (s, 16H), 4.95 (s, 12H), 4.66 (s, 2H), 4.57 (d, *J* = 2.4 Hz, 2H), 4.52 (s, 2H), 4.36 (t, J = 7.3 Hz, 2H), 4.26 (t, J = 7.2 Hz, 2H), 4.12-4.01 (m, 4H), 2.52 (t, J = 2.4 Hz, 1H), 2.41 (s, 6H), 2.37 (s, 6H), 1.95-1.80 (m, 10H), 1.58-1.45 (m, 6H), 1.35-1.25 (m, 16H). ¹³C NMR (101 MHz, CDCl₃): δ 160.3, 160.2, 160.1, 157.5, 154.8, 149.2, 149.1, 145.1, 144.3, 140.5, 139.4, 139.3, 136.9, 132.2, 132.1, 128.7, 128.1, 127.7, 126.9, 125.2, 123.5, 123.4, 122.5, 122.4, 114.2, 106.9, 106.5, 105.4, 101.8, 101.6, 75.5, 72.5, 70.2, 70.1, 68.2, 65.9, 63.9, 60.0, 50.5, 50.4, 30.5, 30.4, 29.8, 29.5, 29.4, 29.1, 26.6, 26.3, 16.9, 16.8. HRMS (ESI): Calcd for C₁₆₀H₁₆₃N₈O₁₉: 2500.2035 [M+H]⁺. Found: 2500.2012.



[2]Rotaxane 1⁴⁺•4PF₆⁻. A solution of compounds S12 (100 mg, 0.04 mmol), S6 (67.4 mg, 0.04 mmol), CBPQT⁴⁺•4PF₆-^[7] (44 mg, 0.04 mmol), TBTA (4.3 mg) and Cu(MeCN)₄PF₆ (5.9 mg) in acetone (7 mL) was stirred for 24 h at room temperature. The solvent was evaporated and the resulting solid was triturated with dichloromethane (5 mL). The organic layer was washed with water (2 mL \times 3) and then concentrated. The resulting residue was subjected to column chromatography (2% NH₄PF₆ in acetone) to afford [2]rotaxane 1-4PF₆ as a green solid (45 mg, 21%). ¹H NMR (400 MHz, CD₃CN): δ 9.97 (s, 2H), 8.96 (s, 8H), 8.85 (s, 1H), 8.60 (d, J = 7.9 Hz, 1H), 8.55 (d, J = 7.9 Hz, 1H), 8.35 (d, J 1H), 7.91 (s, 8H), 7.78-7.55 (m, 16H), 7.46 (d, *J* = 6.1 Hz, 4H), 7.35 (s, 6H), 7.27-7.09 (m, 46H), 7.01 (s, 2H), 6.81-6.72 (m, 2H), 6.63-6.57 (m, 2H), 6.50 (s, 12H), 6.43 (s, 2H), 6.38 (s, 7H), 6.01-5.85 (m, 2H), 5.64 (s, 8H), 5.01-4.76 (m, 19H), 4.73 (s, 12H), 4.42 (d, *J* = 18.8 Hz, 4H), 4.26 (s, 2H), 4.18-4.06 (m, 4H), 4.05-3.87 (m, 12H), 3.84-3.60 (m, 26H), 3.60-3.49 (m, 4H), 3.40-3.17 (m, 6H), 3.00 (s, 3H), 2.23 (d, J = 18.8 Hz, 12H), 1.88-1.77 (m, 4H), 1.76-1.45 (m, 16H), 1.33-1.10 (m, 38H), 1.10 (s, 12H). ¹³C NMR (126 MHz, CD₃CN): δ 169.4, 166.7, 164.2, 164.1, 160.9, 160.8, 160.7, 158.9, 158.8, 155.5, 155.4, 154.4, 149.6, 149.5, 149.0, 148.9, 148.2, 146.6, 146.5, 146.1, 145.4, 144.6, 142.7, 142.0, 140.7, 140.6, 138.0, 137.0, 136.9, 133.4, 133.2, 133.1, 132.4, 132.3, 131.8, 131.5, 130.8, 129.7, 129.6, 129.4, 128.8, 128.5, 128.0, 127.9, 127.8, 127.7, 127.6, 127.5, 126.8, 126.3, 126.2, 126.1, 126.0, 125.9, 125.8, 125.7, 125.5, 125.3, 124.9, 124.7, 124.1, 124.0, 123.9, 120.9, 120.5, 120.1, 114.7, 109.3, 109.2, 109.1, 107.4, 106.6, 106.5, 102.3, 75.5, 72.5, 71.8, 71.5, 71.2, 71.1, 71.0, 70.9, 70.7, 70.5, 70.1, 69.8, 69.1, 69.0, 66.3, 65.5, 64.3, 63.9, 63.4, 63.0, 50.9, 50.8, 50.7, 40.5, 36.2, 36.1, 31.6, 30.9, 30.8, 30.7, 30.5, 30.3, 30.2, 30.1, 30.0, 29.9, 29.6, 27.8, 27.2, 27.1, 26.9, 26.9, 26.8, 24.5, 24.4, 23.7, 17.0. HRMS (ESI): Calcd for C₂₈₁H₃₀₅F₁₂N₁₉O₃₅P₂S₆: 2495.0174 [M-2PF₆-]²⁺. Found: 2495.0173. HRMS (ESI): Calcd for $C_{281}H_{305}F_6N_{19}O_{35}PS_6$: 1615.0234 [M-3PF₆-]³⁺. Found:1615.0268.

References:

- 1. X. Guo, D. Zhang, H. Zhang, Q. Fan, W. Xu, X. Ai, L. Fan, D. Zhu, *Tetrahedron* **2003**, *59*, 4843-4850.
- X.-L. Qui, G. Li, G. Wu, J. Zhu, L. Zhou, P.-L. Chen, A. R. Chamberlin, W.-H. Lee, J. Med. Chem. 2009, 52, 1757-1767.
- K.-D. Zhang, X. Zhao, G.-T. Wang, Y. Liu, Y. Zhang, H.-J. Lu, X.-K. Jiang, Z.-T. Li, Angew. Chem. Int. Ed. 2011, 50, 9866-9870.
- 4. M. Tonga, G. Y. Tonga, G. Seber, O. Gok, A. Sanyal, J. Polym. Sci. A 2013, 51, 5029-5037.
- 5. N. Ardes-Guisot, D. S. Alonzi, G. Reinkensmeier, T. D. Butters, C. Norez, F. Becq, Y. Shimada, S. Nakagawa, A. Kato, Y. Bleriot, M. Sollogoub, B. Vauzeilles, *Org. Biomol. Chem.* **2011**, *9*, 5373-

5388.

- 6. A. Coskun, D. C. Friedman, H. Li, K. Patel, H. A. Khatib, J. F. Stoddart, J. Am. Chem. Soc. 2009, 131, 2493-2495.
- P. L. Anelli, P. R. Ashton, R. Ballardini, V. Balzani, M. Delgado, M. T. Gandolfi, T. T. Goodnow, A. E. Kaifer, D. Philp, M. Pietraszkiewicz, L. Prodi, M. V. Reddington, A. M. Z. Slawin, N. Spencer, J. F. Stoddart, S. C. Vicent, D. J. William, *J. Am. Chem. Soc.* 1992, *114*, 193-218.



Figure S1. Absorption spectra of [2]rotaxane $1.4PF_6(50 \mu M)$ in MeCN and CHCl₃ (1:1) at 298 K: a) The original solution; b) After Fe(ClO₄)₃ (1 equiv) was added; c) After NEt₃ (25 equiv) was added; and d) Recorded after 20 min.



Figure S2. Absorption spectra of [2]rotaxane $1.4PF_6$ (50 µM) in MeCN at 298 K: a) The original solution; b) After Fe(ClO₄)₃ (1 equiv) was added; c) After NEt₃ (25 equiv) was added; and d) Recorded after 20 min.



Figure S3. The UV/Vis spectra of the linear component (LC) (50 μ M) in MeCN and CHCl₃ (1:1) at 298 K: a) The original solution; b) After irradiating the solution with 365 nm light for 10 min; c) After Fe(ClO₄)₃ (1.0 equiv) was added; and d) After NEt₃ (25 equiv) was added.



Figure S4. UV/vis spectra of [2]rotaxane $1^{4+} \cdot 4PF_6^-$ (50 µM) in MeCN and CHCl₃ (1:1) at 298 K: a) Before (black) and after (red) Fe(ClO₄)₃ (1.0 equiv) was added; b) Before (black) and after (red) irradiation with 365 nm light; c) Before (black) and after (red) NEt₃ (25 equiv) was added and recorded immediately; and d) Recorded immediately (black) and 3 h later (red) after NEt₃ was added.



Figure S5. UV/vis spectra of [2]rotaxane $1^{4+} \cdot 4PF_6^-$ (50 µM) in MeCN at 298 K: a) Before (black) and after (red) Fe(ClO₄)₃ (1.0 equiv) was added; b) Before (black) and after (red) irradiation with 365 nm light; c) Before (black) and after (red) NEt₃ (25 equiv) was added and recorded immediately; and d) Recorded immediately (black) and 2 h later (red) after NEt₃ was added.



Figure S6. Left: Time-dependent UV/Vis spectra of [2]rotaxane $1.4PF_6$ in MeCN and CHCl₃ (1:1) at 298 K obtained after NEt₃ (25 equiv) was added to the sample shown in Figure S4. Right: The plot of the C/C₀ (C₀ was the initial concentration of MSCC after reduction and C was the concentration of MSCC after time t) ratio versus the recording time.



Figure S7. Left: Time-dependent UV/Vis spectra of [2]rotaxane $1.4PF_6$ in MeCN and CHCl₃ (1:3) at 298 K obtained after NEt₃ (25 equiv) was added to the sample shown in Fig. 3 in the text. Right: The plot of the C/C₀ (C₀ was the initial concentration of MSCC after reduction and C was the concentration of MSCC after time t) ratio versus the recording time.



Figure S8. Left: Time-dependent UV/Vis spectra of [2]rotaxane $1.4PF_6$ in MeCN at 298 K obtained after NEt₃ (25 equiv) was added to the sample shown in Figure S5. Right: The plot of the C/C₀ (C₀ was the initial concentration of MSCC after reduction and C was the concentration of MSCC after time t) ratio versus the recording time.



Figure S9. The UV/Vis spectra of [2]rotaxane $1.4PF_6$ (50 µM) in MeCN and CHCl₃ (1:3) at 298 K: a) The original solution; b) After irradiating the solution with 365 nm light for 10 min; c) After Fe(ClO₄)₃ (1.0 equiv) was added; and d) Recorded immediately and e) 3 h later after NEt₃ (25 equiv) was added.



Figure S10. Left: Time-dependent UV/Vis spectra of [2]rotaxane $1.4PF_6$ in MeCN and CHCl₃ (1:3) at 298 K obtained after NEt₃ (25 equiv) was added to the sample shown in Figure 4. Right: The plot of the C/C₀ (C₀ was the initial concentration of MSCC after reduction and C was the concentration of MSCC after time t) ratio versus the recording time.



Figure S11. The UV/Vis spectra of [2]rotaxane $1.4PF_6$ (50 µM) in MeCN and CHCl₃ (1:1) at 298 K: a) The original solution; b) After irradiating the solution with 365 nm light for 10 min; c) After Fe(ClO₄)₃ (1.0 equiv) was added; and d) Recorded immediately and e) 3.5 h later after NEt₃ (25 equiv) was added.



Figure S12. The UV/Vis spectra of [2]rotaxane $1.4PF_6$ (50 µM) in MeCN at 298 K: a) The original solution; b) After irradiating the solution with 365 nm light for 10 min; c) After Fe(ClO₄)₃ (1.0 equiv) was added; and d) Recorded immediately and e) 3 h later after NEt₃ (25 equiv) was added.



Figure S13. UV/vis spectra of [2]rotaxane $1^{4+} \cdot 4PF_6^-$ (50 µM) in MeCN and CHCl₃ (1:1) at 298 K: a) Before (black) and after (red) irradiation with 365 nm light for 10 min; b) Before (black) and after (after) Fe(ClO₄)₃ (1.0 equiv) was added; c) Before (black) and after (red) NEt₃ (25 equiv) was added and recorded immediately; and d) Recorded immediately (black) and 3.5 h later (red) after NEt₃ was added.



Figure S14. UV/vis spectra of [2]rotaxane $1^{4+} \cdot 4PF_6^-$ (50 µM) in MeCN at 298 K: a) Before (black) and after (red) irradiation with 365 nm light; b) Before (black) and after (after) Fe(ClO₄)₃ (1.0 equiv) was added; c) Before (black) and after (red) NEt₃ (25 equiv) was added and recorded immediately; and d) Recorded immediately (black) and 90 min later (red) after NEt₃ was added.



Figure S15. The UV/Vis spectra of [2]rotaxane $1.4PF_6$ (50 µM) in MeCN and CHCl₃ (1:1) at 298 K: a) The original solution; b) After irradiating the solution with 365 nm light for 10 min; c) After Fe(ClO₄)₃ (1.0 equiv) was added and recorded immediately; and recorded after d) 131 s, e) 260 s, f) 400 s and g) 525 s.



Figure S16. The UV/Vis spectra of [2]rotaxane $1.4PF_6$ (50 µM) in MeCN at 298 K: a) The original solution; b) After irradiating the solution with 365 nm light for 10 min; c) After Fe(ClO₄)₃ (1.0 equiv) was added and recorded immediately and recorded after d) 156 s, e) 299 s, f) 448s, g) 628 s and h) 758s, i) 892 s.



Figure S17. Top: UV/vis spectra of [2]rotaxane $1^{4+} \cdot 4PF_6^-$ (50 µM) in MeCN and CHCl₃ (1:3) at 298 K: a) Before (black) and after (red) irradiation with 365 nm light. Bottom: Time-dependent absorption changes at 360 nm observed upon leaving the irradiated solution in the dark.



Figure S18. The UV/Vis spectra of [2]rotaxane $1.4PF_6$ (50 µM) in MeCN and CHCl₃ (1:3) at 298 K: a) The original solution; b) After irradiating the solution with 365 nm light for 10 min; c) After Fe(ClO₄)₃ (1.0 equiv) was added and recorded immediately; and Recorded after d) 2min10s and e) 6min40s.



Figure S19. Left: Time-dependent UV/Vis spectra of [2]rotaxane $1.4PF_6$ in MeCN and CHCl₃ (1:1) at 298 K obtained after NEt₃ (25 equiv) was added to the sample shown in Figure S13. Right: The plot of the C/C₀ (C₀ was the initial concentration of MSCC after reduction and C was the concentration of MSCC after time t) ratio versus the recording time.



Figure S20. Left: Time-dependent UV/Vis spectra of [2]rotaxane $1.4PF_6$ in MeCN at 298 K obtained after NEt₃ (25 equiv) was added to the sample shown in Figure S14. Right: The plot of the C/C₀ (C₀ was the initial concentration of MSCC after reduction and C was the concentration of MSCC after time t) ratio versus the recording time.



Figure S21. ¹H NMR spectrum (400 MHz) of compound S2 in CD₃CN at 298 K.



Figure S22. ¹³C NMR spectrum (100 MHz) of compound S2 in CD₃CN at 298 K.



Figure S23. ¹H NMR spectrum (400 MHz) of compound S3 in CD₃CN at 298 K.



Figure S24. ¹³C NMR spectrum (100 MHz) of compound S3 in CD₃CN at 298 K.



Figure S25. ¹H NMR spectrum (400 MHz) of compound S6 in acetone-d₆ at 298 K.



Figure S26. ¹³C NMR spectrum (100 MHz) of compound S6 in acetone-d₆ at 298 K.



Figure S27. ¹H NMR spectrum (400 MHz) of compound S8 in CDCl₃ at 298 K.



Figure S28. ¹³C NMR spectrum (100 MHz) of compound S8 in CDCl₃ at 298 K.



Figure S29. ¹H NMR spectrum (400 MHz) of compound S9 in CDCl₃ at 298 K.



Figure S30. ¹³C NMR spectrum (100 MHz) of compound S9 in CDCl₃ at 298 K.



Figure S31. ¹H NMR spectrum (400 MHz) of compound S10 in CDCl₃ at 298 K.



Figure S32. ¹³C NMR spectrum (100 MHz) of compound S10 in CDCl₃ at 298 K.



Figure S33. ¹H NMR spectrum (400 MHz) of compound S12 in CDCl₃ at 298 K.



Figure S34. ¹³C NMR spectrum (100 MHz) of compound S12 in CDCl₃ at 298 K.



Figure S35. ¹H NMR spectrum (400 MHz) of [2]rotaxane 1^{4+} -4PF₆⁻ in CD₃CN at 298 K.



Figure S36. ¹³C NMR spectrum (100 MHz) of [2]rotaxane 1^{4+} 4PF₆⁻ in CD₃CN at 298 K.